Evaluating the performance of drug-repurposing technologies.
Drug Discov Today
; 27(1): 49-64, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-34400352
ABSTRACT
Drug-repurposing technologies are growing in number and maturing. However, comparisons to each other and to reality are hindered because of a lack of consensus with respect to performance evaluation. Such comparability is necessary to determine scientific merit and to ensure that only meaningful predictions from repurposing technologies carry through to further validation and eventual patient use. Here, we review and compare performance evaluation measures for these technologies using version 2 of our shotgun repurposing Computational Analysis of Novel Drug Opportunities (CANDO) platform to illustrate their benefits, drawbacks, and limitations. Understanding and using different performance evaluation metrics ensures robust cross-platform comparability, enabling us to continue to strive toward optimal repurposing by decreasing the time and cost of drug discovery and development.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Avaliação de Medicamentos
/
Reposicionamento de Medicamentos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Drug Discov Today
Ano de publicação:
2022
Tipo de documento:
Article